Innovus Pharmaceuticals, Inc - INNV

1.7500
USD +1.6150 (11.9630%)
Trade

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company’s pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Trade Innovus Pharmaceuticals, Inc at these brokers
1 2 3 4 5 6 7 8 9 10
3.75
  • Platforms: Andriod App, iOS App, Mobile App, WebTrader
  • License: Not Applicable
Your capital is at risk
1 2 3 4 5 6 7 8 9 10
3.75
  • Platforms: Andriod App, Apple App, iOS App, MetaTrader 4, MetaTrader 5, Mobile App, Proprietary, WebTrader
  • License: CySEC, FCA UK
Your capital is at risk
1 2 3 4 5 6 7 8 9 10
4.5
  • Platforms: Andriod App, Apple App, iOS App, Mobile App, WebTrader
  • License: ASIC, CySEC, FCA UK
Your capital is at risk